(AOF) – Abionyx Pharma announces consolidated turnover for the first nine months of the year of 3.59 million euros “after elimination of intra-group operations”. The new generation biotech indicates that as of September 30, 2023, its cash flow stands at 1.7 million euros. This cash position does not include the capital increase of 3 million euros carried out on October 6, 2023 nor the reimbursement of the Iris Pharma CIR of 736,000 euros which also took place in October.
Abionyx announces that in September 2023, CER-001 was provided under Compassionate Access to a new patient in Italy with LCAT Deficiency, a rare kidney disease with no existing treatment. This is the fifth patient suffering from LCAT deficiency, known as Norum disease, to be treated with CER-001 in Europe.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
